Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
So low cost! It's worth geting penis vibrator in our Sex Toys Store.
Popular Articles

$500,000 Gruber Genetics Prize Awarded To Cancer Geneticist Janet Davison Rowley
Janet Davison Rowley, MD, a founder in the field of cancer cytogenetics and a renowned leader in molecular oncology, will receive the 2009 Genetics Prize of The Peter and Patricia Gruber Foundation. She is being honored with the prestigious international award for discoveries of recurrent chromosomal abnormalities in leukemias and lymphomas - discoveries that have revolutionized how cancer is understood and treated. Currently the Blum-Riese Distinguished Service Professor at the University of Chicago, Rowley is also being honored for her critical national and international leadership in the biomedical research community. The Prize will be presented in Honolulu, Hawaii, on October 23 at the 59th Annual Meeting of the American Society of Human Genetics.
pharmacy online Dentisti fiume
U.S. Food And Drug Administration Approves ONGLYZA™ (saxagliptin) For The Treatment Of Type 2 Diabetes Mellitus In Adults
Bristol-Myers Squibb Company (NYSE: BMY) and AstraZeneca (NYSE: AZN) today announced that the U.S. Food and Drug Administration (FDA) approved ONGLYZA™ (saxagliptin), a dipeptidyl peptidase-4 (DPP4) inhibitor. ONGLYZA is indicated as an adjunct to diet and exercise to improve blood sugar (glycemic) control in adults for the treatment of type 2 diabetes mellitus. ONGLYZA once daily can be used in combination with commonly prescribed oral anti-diabetic medications - metformin, sulfonylureas or thiazolidinediones (TZD) - or as a monotherapy to significantly reduce glycosylated hemoglobin (A1C) levels. ONGLYZA should not be used for the treatment of type 1 diabetes or for the treatment of diabetic ketoacidosis (high levels of certain acids, known as ketones, in the blood or urine). ONGLYZA has not been studied in combination with insulin.
News of the day
New Survey Highlights Growing Concern About Risk Of Infection In Cancer Patients And Emerging Antibiotic Resistance
Amgen (Nasdaq: AMGN) announced the results of a national Harris Interactive, Inc. survey indicating that the vast majority of oncologists and infectious disease (ID) specialists are highly concerned about the negative impact infection may have on treatment outcomes in chemotherapy patients, as well as emerging antibiotic resistance. Nearly all oncologists surveyed (92 percent) believe it is important for cancer patients to prevent infections to achieve successful treatment outcomes. Antibiotic resistance is a growing concern among the majority of physicians surveyed, with 96 percent of ID specialists and 79 percent of oncologists reporting an increase in antibiotic-resistant infections in cancer patients over the past five years. Both groups of physicians report methicillin-resistant Staphylococcus aureus (MRSA) infections as the most commonly observed in chemotherapy patients.
Diagnostics

Glasgow Based BioOut Active In Flu Vaccine Testing

BioOut is a strategic partner for several of the world"s leading vaccine manufacturers. As such, BioOut is currently working with partners on projects to develop vaccines against Pandemic Influenza (Swine Flu and Avian Flu). BioOut is a forward-thinking contract testing organisation which has been inspected and approved to GMP standard by the UK MHRA. The company has wide experience of testing and releasing virus vaccine, including Pandemic and Seasonal flu, and provides the release testing of vaccine lots to meet the European Pharmacopeia release guidelines. BioOut has expertise in the handling of vaccine harvests and neutralisation of the virus lots for testing. In a relatively new innovation BioOut can offer an EP compliant alternative method to the lengthy and costly Mycoplasma test EP 2.6.1; PCR methodologies are used to detect mycoplasma, this can reduce the timelines for this test to 2 days rather than the 35 days this test would normally require and reduce costs by a factor of 4. Nexxus Scotland


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009